European drug regulators have recommended against approving Zevra Therapeutics' drug arimoclomol for the treatment of Niemann-Pick disease type C (NPC), a rare neurodegenerative disorder.
Zevra said Friday that the European Commission is expected to issue its final decision on the marketing authorization application for the drug within 67 days.
The negative opinion on the application came from the European Medicines Agency's Committee for Medicinal Products for Human Use, which is responsible for assessing the quality, safety and efficacy of medicines, and recommending whether the European Commission should approve them.
Zevra said it believes the data it provided for arimoclomol, including from a Phase 2/3 trial, supports its therapeutic benefit in NPC.
The company said it will continue to support eligible patients currently receiving arimoclomol through its global expanded access program, and that it will continue to advance scientific understanding of NPC.
"We are deeply disappointed by the CHMP's opinion, particularly given the significant unmet medical need faced by individuals and families living with NPC," Chief Executive Neil McFarlane said.
NPC affects about 1,000 people in Europe.
Zevra's stock slid 6.0% to $10.49 in premarket trading Friday.
Comments